Benjamin P. Levy, MD
Established and emerging biomarkers are demonstrating predictive value with immunotherapy for patients with non–small cell lung cancer (NSCLC), but equally as compelling are those that can predict lack of response, said Benjamin P. Levy, MD.
State of the Science Summit™ on Advanced Non–Small Cell Lung Cancer, Levy, assistant professor of Oncology, clinical director, Medical Oncology, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospital, discussed established and emerging biomarkers that could have predictive value with immunotherapy.
OncLive: What biomarkers should physicians be aware of?
: We have come a long way. We know that PD-L1 remains a biomarker. The cutoff point of 50% is still used to drive decision-making. There are other biomarkers to consider, such as TMB. This is a story that is beginning to be told. I don't think the story is completely done yet. TMB may be another biomarker to look at that may predict efficacy to either single checkpoint inhibitors or dual checkpoint blockade, as we have seen from recent data published in the New England Journal of Medicine
mutations also may predict lack of benefit to immunotherapy.
Are PD-L1 and TMB routinely tested for at Johns Hopkins Medicine?
We're still working out TMB in-house. We are still waiting to get it validated, but PD-L1 is of course tested for. EGFR
mutations are tested for, and KRAS
is also looked at. We do a next-generation panel that gives you the co-alterations with KRAS
, as well. LKB1
, a marker that may demonstrate lack of benefit to immunotherapy, is also tested in our next-generation panel.
... to read the full story